Literature DB >> 15788579

Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT.

David W Barker1, Ronald J Zagoria, Kathryn A Morton, Peter V Kavanagh, Perry Shen.   

Abstract

OBJECTIVE: Our objective was to review the CT appearance of liver metastases after radiofrequency ablation and to describe the imaging findings of and utility of (18)F-FDG PET and PET/CT in assessing tumor recurrence after ablation.
CONCLUSION: (18)F-FDG PET and PET/CT can provide added diagnostic information compared with conventional imaging in patients after radiofrequency ablation of liver metastases and can be useful in guiding repeat ablation procedures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788579     DOI: 10.2214/ajr.184.4.01841096

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study.

Authors:  Françoise Bonichon; Jean Palussière; Yann Godbert; Marina Pulido; Edouard Descat; Anne Devillers; Catherine Meunier; Sophie Leboulleux; Thierry de Baère; Claire Galy-Lacour; Laurent Lagoarde-Segot; Anne-Laure Cazeau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-17       Impact factor: 9.236

2.  Heme products post-radiofrequency ablation obscure tumor recurrence on MR but not on PET-CT.

Authors:  Syed Ramisa Ehsan; Casey E Gooden; David M Schuster
Journal:  Nucl Med Mol Imaging       Date:  2012-04-27

3.  Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT.

Authors:  Long Sun; Yong-Song Guan; Wei-Min Pan; Zuo-Ming Luo; Ji-Hong Wei; Long Zhao; Hua Wu
Journal:  World J Hepatol       Date:  2009-10-31

4.  Value of percutaneous radiofrequency ablation with or without percutaneous vertebroplasty for pain relief and functional recovery in painful bone metastases.

Authors:  Frédéric Clarençon; Betty Jean; Hang-Phuong Pham; Evelyne Cormier; Gilbert Bensimon; Michèle Rose; Philippe Maksud; Jacques Chiras
Journal:  Skeletal Radiol       Date:  2011-11-13       Impact factor: 2.199

5.  Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Wei Teng; Ka-Wai Liu; Chen-Chun Lin; Wen-Juei Jeng; Wei-Ting Chen; I-Shyan Sheen; Chun-Yen Lin; Shi-Ming Lin
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

6.  Kinetic analysis of FDG in rat liver: effect of dietary intervention on arterial and portal vein input.

Authors:  Sudheer D Rani; Samuel T Nemanich; Nicole Fettig; Kooresh I Shoghi
Journal:  Nucl Med Biol       Date:  2013-02-28       Impact factor: 2.408

7.  Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions.

Authors:  Michelle S Bradbury; Evan Phillips; Pablo H Montero; Sarah M Cheal; Hilda Stambuk; Jeremy C Durack; Constantinos T Sofocleous; Richard J C Meester; Ulrich Wiesner; Snehal Patel
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 8.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

9.  18F-FDG PET/CT performed immediately after percutaneous ablation to evaluate outcomes of the procedure: preliminary results.

Authors:  Juliana Romanato; Marcos Roberto Menezes; Allan de Oliveira Santos; Regis Otaviano Franca Bezerra; Mariana Cunha Lopes Lima; Elba Etchebehere
Journal:  Radiol Bras       Date:  2019 Jan-Feb

10.  Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate.

Authors:  Anne Roivainen; Alexandru Naum; Heikki Nuutinen; Rauli Leino; Heimo Nurmi; Kjell Någren; Riitta Parkkola; Johanna Virtanen; Markku Kallajoki; Harry Kujari; Jari Ovaska; Peter Roberts; Marko Seppänen
Journal:  EJNMMI Res       Date:  2013-02-27       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.